A randomized trial of chemotherapy with carmustine, etoposide, cytarabine, and melphalan (BEAM) plus peripheral stem cell transplantation (PBSCT) vs single-agent high-dose chemotherapy followed by BEAM plus PBSCT in patients with relapsed Hodgkin's disease (HD-R2)
作者
J. Glossmann,Andreas Josting,Beate Pfistner,U. Paulus,Andreas Engert
出处
期刊:Annals of Hematology [Springer Science+Business Media] 日期:2002-08-01卷期号:81 (8): 424-429被引量:14